| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | CI-49 |
| WB Predicted band size | 53 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human NDUFS2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于NDUFS2抗体的3篇参考文献示例(内容为模拟生成，非真实文献)：
1. **文献名称**：*NDUFS2 deficiency in mitochondrial complex I drives mitochondrial encephalopathy pathogenesis*
**作者**：Smith A, et al.
**摘要**：研究通过Western blot和免疫组化分析，使用NDUFS2抗体发现其在Leigh综合征患者中表达显著降低，揭示了复合物I功能障碍与神经退行性病变的关联。
2. **文献名称**：*Antibody-based profiling of mitochondrial complex I subunits in cardiac ischemia*
**作者**：Chen L, et al.
**摘要**：利用NDUFS2抗体检测心肌缺血模型中线粒体复合物I的亚基变化，发现NDUFS2蛋白水平下降与氧化应激损伤密切相关。
3. **文献名称**：*A novel NDUFS2 mutation identified by immunohistochemistry in pediatric mitochondrial disease*
**作者**：Garcia R, et al.
**摘要**：通过NDUFS2抗体的免疫染色技术，在一组儿童线粒体疾病患者中鉴定出新的NDUFS2基因突变，证实抗体在临床诊断中的应用价值。
(注：以上文献信息为模拟生成，实际引用需查询PubMed等数据库获取真实文献。)
The NDUFS2 antibody is a crucial tool in studying mitochondrial complex I (NADH:ubiquinone oxidoreductase), a key component of the electron transport chain. NDUFS2 (NADH dehydrogenase [ubiquinone] iron-sulfur protein 2) is a nuclear-encoded subunit of complex I, essential for its assembly and catalytic activity. It contains iron-sulfur clusters critical for electron transfer during oxidative phosphorylation. Mutations in the NDUFS2 gene are linked to mitochondrial disorders, such as Leigh syndrome, characterized by neurodegeneration and energy deficiency.
Researchers use NDUFS2 antibodies to investigate protein expression, localization, and complex I integrity in diseases like mitochondrial encephalopathies, Parkinson’s disease, and cancer. These antibodies are typically validated in applications like Western blotting, immunofluorescence, and immunohistochemistry to assess tissue-specific expression or pathological changes. They also aid in studying cellular responses to oxidative stress, metabolic adaptations, and therapeutic interventions targeting mitochondrial dysfunction.
Commercial NDUFS2 antibodies are often raised in rabbits or mice against synthetic peptides or recombinant protein fragments. Specificity is confirmed via knockout controls or siRNA knockdown. Proper validation ensures reliability in differentiating NDUFS2 from homologous proteins. As mitochondrial research expands, NDUFS2 antibodies remain vital for unraveling the molecular mechanisms of energy metabolism and disease pathogenesis.
×
